Christopher J. Hoimes, DO, assistant professor, Department of Medicine Division of Hematology and Oncology, School of Medicine, member, GU Malignancies Program, Case Comprehensive Cancer Center, Case Western Reserve University, discusses the results of the EV-103 trial in patients with locally advanced or metastatic urothelial cancer.

The phase Ib/II EV-103 trial, a single-arm, multi-site study, examined enfortumab vedotin with pembrolizumab (Keytruda) in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer, explains Hoimes. Patients were put in a dose-escalation cohort as well as in a dose-expansion cohort.

The dose-escalation cohort identified no dose-limiting toxicities and a randomized recommended phase II dose of 1.25 mg/kg of enfortumab vedotin given on days 1 and 8, concludes Hoimes.

Videos

Christopher J. Hoimes, DO, discusses the results of the EV-103 trial in patients with locally advanced or metastatic urothelial cancer.

Christopher J. Hoimes, DO

Articles

Dr. Hoimes on EV-103 Results in Urothelial Cancer